Heterologous prime-boost regimens—using different vaccine platforms for first and second doses—have generally shown greater or at least comparable immunogenicity compared with some homologous schedules, especially when an adenoviral-vector prime is followed by an mRNA boost. Evidence from randomized and observational studies supports this pattern, with consistent findings across independent groups.
Evidence from clinical studies
Shaw RH at the University of Oxford reported results from the Com-COV trial showing that a prime with the ChAdOx1 adenoviral vaccine followed by an mRNA boost produced robust antibody and T cell responses compared with two doses of ChAdOx1. Hillus F at Charité — Universitätsmedizin Berlin found similar increases in neutralizing antibody titers after heterologous ChAdOx1 then BNT162b2 compared with homologous ChAdOx1. Pozzetto I at Aix-Marseille University observed enhanced neutralization against SARS-CoV-2 variants in participants who received mixed adenoviral and mRNA regimens. These independent reports converge on the conclusion that heterologous schedules can raise humoral and cellular immunity beyond what is typically seen with two doses of adenoviral-vector vaccines, and at least match two-dose mRNA schedules in many measures.
Causes and implications
The immunological rationale is that different platforms stimulate complementary arms of the immune system. An adenoviral vector often induces strong T cell priming and a broad innate signal, while mRNA vaccines drive potent spike-specific antibody production. Using two different platforms can reduce anti-vector immunity that might blunt a repeated viral-vector dose and can broaden the quality of the response. Clinically, improved neutralization breadth may translate to better protection against variants and longer durability of protection, although direct correlates with long-term real-world effectiveness continue to be studied.
Heterologous regimens also have operational and cultural relevance. For regions facing supply constraints, mixing platforms increases flexibility and can accelerate coverage. Temporary increases in short-term reactogenicity—more fever, fatigue, or local soreness—were reported by trialists including Shaw RH at the University of Oxford, but serious adverse events remained rare. Public communication must address local trust and preferences, as perceptions of mixing vaccines vary by country and community.
Overall, current high-quality evidence from established research groups supports heterologous prime-boost as a viable and often more immunogenic option than homologous adenoviral schedules, with real-world policy implications for improving population-level protection.